Development and validation of a PSMA-positive triple-negative breast cancer mouse model for preclinical targeted radionuclide therapiesBenjamin Chaussin(Inserm), E. Jouberton(Inserm)Scientific ReportsFebruary 16, 202610.1038/s41598-026-36724-7Cited by 0SaveCiteExport RISWatch citationsRelated PapersFrom Hurdles to Breakthroughs: Building and Validating a PSMA-positive Triple-Negative Breast Cancer Mouse Model for Preclinical Targeted Radionuclide Therapy|Research Square|2025|0